EBV-Positive DLBCL clinical trials at UCSF
1 research study open to eligible people
EBV-Positive DLBCL is a type of lymphoma. There's a clinical trial at UCSF for patients with relapsed/refractory lymphomas caused by the Epstein-Barr virus. The trial is testing a combination of nanatinostat and valganciclovir.
Showing trials for
Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
open to eligible people ages 18 years and up
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
San Francisco, California and other locations
Last updated: